NCT03925857View on ClinicalTrials.gov

Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 27, 2019

Primary Completion Date

December 10, 2019

Study Completion Date

January 12, 2020

Conditions
Organ Dysfunction Syndrome Sepsis
Interventions
BIOLOGICAL

Allocetra-OTS

Allocetra-OTS contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution.

Trial Locations (1)

12000

Hadassah Medical Center, Jerusalem

Sponsors
All Listed Sponsors
lead

Enlivex Therapeutics Ltd.

INDUSTRY

NCT03925857 - Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS | Biotech Hunter | Biotech Hunter